rp-hplc method for the determination of losartan potassium ... · rp-hplc method for the...

4

Click here to load reader

Upload: truongnhu

Post on 24-Mar-2019

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: RP-HPLC Method for the Determination of Losartan Potassium ... · RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage Form ... Brenner BM, Cooper

www.ijpsonline.com

Indian Journal of Pharmaceutical Sciences108 January - February 2010

Accepted 3 January 2010Revised 11 September 2009

Received 11 July 2007Indian J. Pharm. Sci., 2010, 72 (1): 105-108

ACKNOWLEDGEMENTS

We thank Dr. T. K. Paul, Sr. Scientist, Botanical Survey of India, Kolkata for identification and authentication of two aroids species used in this experiment.

REFERENCES

1. Bhattacharya SK. Chiranjibi banoishidhi. Vol. 3. Kolkata: Ananda Publishers; 2005. p. 133-40.

2. Horborne JB. Secondary plant products. In: Bell EA, Charlwood BV, editors. Plant Phenolics: encyclopedia of plant physiology. Vol. 8. New York: Springer-Verlag; 1980. p. 329-402.

3. Mabe K, Yamada M, Oguni I, Takahashi T. In-vitro and in-vivo activities of tea catechins against H. pylori. Am Soc Microbiol 1999;3:1788-91.

4. Hitchen CH, Gabalawy HS. Oxidation in Rheumatoid arthritis. Arthritis Res Ther 2004;6:265-78.

5. Pajohk F, Riedisser A, Henke M, McBride WA, Fiebich B. The effects of Tea extracts on proinfl ammatory signaling. BMC Med 2006;4:28-32.

6. Halliwell B. The antioxidant paradox. Lancet 2000;355:1179-80.

7. Young IS, Woodside J. Antioxidants in health and disease. J Clin Pathol 2001;54:176-86.

8. Heineck JW. Oxidative stress-New approaches to diagnosis and prognosis in the atherosclerosis. Am J Cardiol Am 2003;91:12-6.

9. Cheesman KH, Slater TF. Free radicals in medicine. Br Med Bull 1993;49:475-724.

10. Raj KJ, Shalini K. Flavonoids: A review of biological activities. Indian Drugs 1999;36:668-76.

11. Dhalwal K, Deshpande YS, Purohit AP, Kadam SS. Evaluation of the antioxidant activity of Sida cordifolia, J Pharm Biol 2005;43:754-61.

12. Al-Bandak G, Oreopoulou V. Antioxidant properties and composition of Majorana syriaca extracts. Eur J Lipid Sci Technol 2007;109:247-55.

13. Badami S, Prakash O, Dongre SH, Suresh B. In vitro antioxidant properties of Solanum pseudocapsicum leaf extracts. Indian J Pharmacol 2005;37:251-52.

14. Wiseman SA, Balentine DA, Frie B. Antioxident in tea. Crit Rev Food Sci 1997;37:705-18.

*Address for correspondenceE-mail: [email protected]

RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage FormK. SRINIVASA RAO* AND K. SRINIVASRoland Institute of Pharmaceutical Sciences, Berhampur-760 010, Orissa, India.

Rao and Srinivas: RP-HPLC Determination of Losartan Potassium and Ramipril

A simple, specifi c and accurate reverse phase liquid chromatographic method was developed for the simultaneous determination of losartan potassium and ramipril in table dosage forms. A hypersil ODS C18, 4.6×250 mm, 5 µm column in isocratic mode, with mobile phase acetonitrile:methanol:10 mM tetra butyl ammonium hydrogen sulphate in water in the ratio of 30:30:40% v/v/v was used. The fl ow rate was 1.0 ml/min and effl uent was monitored at 210 nm. The retention times of losartan potassium and ramipril were 4.7 and 3.3 min, respectively. The linearity range for losartan potassium and ramipril were in the range of 0.04-100 µg/ml and 0.2-300 µg/ml, respectively. The proposed method was also validated and successfully applied to the estimation of losartan potassium and ramipril in combined tablet formulations.

Key words: Losartan potassium, ramipril, validation, RP-HPLC

Losartan potassium (LRT) is chemically 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol monopotassium salt. LRT is the fi rst of a unique class of oral antihypertensive agents referred to as angiotensin II receptor antagonists[1]. Ramipril (RAM) is chemically (2S,3aS,6aS)-1[(S)-N-[(S)-1-

carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid-1-ethyl ester. It is an antihypertensive agent. Ramiprilat, the diacid metabolite of ramipril, is a non-sulfhydryl angiotensin converting enzyme inhibitor[2-3]. RAM is converted to ramiprilat by hepatic cleavage of the ester group.

A literature survey regarding quantitative analysis of these drugs revealed that a few methods[4-13]

Azhar
Rectangle
Page 2: RP-HPLC Method for the Determination of Losartan Potassium ... · RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage Form ... Brenner BM, Cooper

www.ijpsonline.com

Indian Journal of Pharmaceutical Sciences 109January - February 2010

100 ml volume fl ask containing 50 ml mobile phase. The mixture was sonicated for 10 min. The volume was made up to 100 ml with mobile phase. The contents were fi ltered through 0.22 μ membrane fi lter. An aliquot portion of the fi ltrate was further diluted to get fi nal concentration of 10 μg/ml of RAM and 100 μg/ml of LRT. This solution was used for the estimation.

The method was validated for accuracy, precision, specifi city, limit of detection, limit of quantifi cation and robustness. The accuracy of the method was determined by calculating recoveries of RAM and LRT by method of standard additions. The intra day and inter-day precision study of RAM and LRT was carried out by estimating the corresponding responses 3 times on the same day and on 3 different days of 3 different concentrations of RAM (1, 2, 5 µg/ml) and LRT (1, 3, 6 µg/ml). The repeatability studies were carried out by estimating response of three different concentrations of RAM and LRT for triplicate and results are reported in terms of relative standard deviation (RSD). For specificity study commonly used excipients (starch, microcrystalline cellulose and magnesium stearate) present in selected tablet formulation were spiked into a pre weighed quantity of drugs. The chromatogram was taken by appropriate dilutions and the quantities of drugs were determined. The limit of detection and limit of quantification of the developed method were determined by injecting progressively low concentrations of the standard solutions using the developed RP-HPLC method. Limit of detection was the concentration that yielded signal to noise ratio (S/N) 3:1 and limit of quantifi cation was the concentration that yielded signal to noise ratio (S/N) 10:1. Robustness was done by small changes in the chromatographic conditions

were reported for the estimation of LRT and RAM individually and only one method is reported so far for the estimation of LRT and RAM in combined dosage forms[14]. This paper described a new RP-HPLC method for the simultaneous estimation of LRT and RAM in combined dosage form using simple mobile phase.

Quantitative HPLC was performed on a binary gradient HPLC with Shimadzu LC10AT and LC10AT VP series HPLC pumps, with a 20 µl injection of sample loop (manual), and SPD 10A VP UV/Vis detector. The output signal was monitored and integrated using Shimadzu Class-VP version 6.12 SP1 software. Hypersil ODS C18 (46 mm×25 cm, 5 µm) column was used for the separation. RAM and LRT were gift samples from Sun Pharma Ltd., Vadodara. Formulation A (loram-5, Unichem Ltd., India) containing 5 mg of RAM and 50 mg of LRT was purchased from a local pharmacy. Purifi ed water was prepared using a Millipore Milli-Q (Bedford, MA, USA) water purification system. Acetonitrile of HPLC grade was purchased from Ranbaxy Fine Chemicals Ltd., New Delhi, India. Tetra butyl ammonium hydrogen sulphate was purchased from Hi-media Laboratories Pvt. Ltd., Mumbai, India. Methanol of HPLC grade was purchased for E-Merck, Mumbai, India.

Stock solutions of the RS drugs were prepared by dissolving 25 mg each of RAM and LRT separately in 15 ml acetonitrile contained in 25 ml volumetric fl asks and sonicated for 20 min and then the volume was made up to 25 ml with mobile phase. From the standard stock solution, mixed standard solution was prepared to contain 5 μg/ml of RAM, 50 μg/ml of LRT.

Twenty tablets, each containing 5 mg of RAM and 50 mg of LRT were weighed and fi nally powdered. A quantity of powder equivalent to 0.5 mg of RAM and 5.0 mg of LRT were weighed and transferred to

TABLE 1: REGRESSION ANALYSIS OF THE CALIBRATION CURVES FOR RAM AND LRTParameters LRT RAMLinearity ranges (mcg/ml) Slope Standard deviation of slope Intercept Standard deviation of intercept Correlation coeffi cient ( r )

0.04 –100 98834 48.383 25877

51.216 0.9993

0.2 – 3004165769.7146802128.4390.9994

LRT is losartan potassium; RAM is ramipril

TABLE 2: SUMMARY OF VALIDATION PARAMETERS FOR THE PROPOSED METHODParameters LRT RAMLOD (µg/ml)LOQ (µg/ml)Accuracy (%)Precision (RSDa, %)Intra day (n=3)Inter day (n=3)ResolutionCapacity factorTheoretical platesTailing factorHETPAssymmetry

0.0710.215

99.08-99.41

0.45-0.560.61-0.82

1.413.42

302711.09

5.6×10-5

1.67

0.110.332

99.52-99.86

0.43-0.780.56-0.98

1.414.5478771.05

4.7×10-5

0.546RSDa indicates relative standard deviation; LRT is losartan potassium; RAM is ramipril

Page 3: RP-HPLC Method for the Determination of Losartan Potassium ... · RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage Form ... Brenner BM, Cooper

www.ijpsonline.com

Indian Journal of Pharmaceutical Sciences110 January - February 2010

and the present method didn’t show any signifi cant change when the critical parameters were modifi ed.

Selection of mobile phase was performed based on resolution, asymmetric factors and theoretical plates obtained for both RAM and LRT. The mobile phase acetonitrile:methanol:10 mM tetrabutylammonium hydrogensulphate (TBHS) in water in the ratio of 30:30:40% v/v/v at flow rate of 1.0 ml/min gave sharp peaks with minimum tailing and good resolution for both RAM and LRT. RAM and LRT were eluted at retention times 3.317 and 4.742 min, respectively with symmetric peak shape (fig. 1). UV overlain spectra of RAM and LRT showed that both the drugs are having appreciable absorbance at 210 nm and therefore 210 nm was selected as the detection wavelength in liquid chromatography.

The linearity of the method was determined at different concentration levels from 0.04 to 100 μg/ml for LRT and 0.2 to 300 μg/ml for RAM using RS drug solutions. The total eluting time was less than 10 min. The linearity of this method was evaluated by linear regression analysis, which was calculated by least square method and the data of regression analysis of the calibration curves are shown in Table 1. The mean±standard deviation (SD) for the slope, intercept and correlation coefficient of standard curves (n=6) were calculated. The represented data

was shown in Table 2. The % recoveries of RAM and LRT were found to be in the range of 99.52–99.86% and 99.08–99.41%, respectively. The proposed liquid chromatographic method was applied to the determination of RAM and LRT in their combined dosage forms. The results of RAM and LRT were comparable with the corresponding labeled amounts (Table 3).

Thus in proposed study, RP-HPLC method has been developed for determination of RAM and LRT in combined dosage forms. The method was validated and found to be simple, sensitive, accurate and precise. The method was successfully applied for determination of drugs in their pharmaceutical formulations and hence the proposed method can be used for routine analysis of RAM and LRT in combined dosage form.

ACKNOWLEDGEMENTS

The authors are thankful to Roland Institute of Pharmaceutical Sciences, Berhampur, Orissa, for providing the laboratory facilities to carryout the present investigation.

REFERENCES

1. Brenner BM, Cooper ME, de Zeeuw D. Effects of losartan on renal

TABLE 3: ASSAY RESULTS OF COMBINED DOSAGE FORM USING PROPOSED METHODFormulation Labeled amount (mg) Amount obtained (mg)b %Recoveryb

LRT RAM LRT RAM LRT RAMA 50 5 51.00±0.4698 5.05±0.0915 102.0± 0.156 101.03±1.83bMean value±standard deviation of three determinations; Tablet A is Loram-5, Unichem Ltd., containing 5 mg of ramipril (RAM) and 50 mg of losartan potassium (LRT).

Fig. 1: Typical chromatogram of LRT and RAMLRT is losartan potassium; RAM is ramipril

Page 4: RP-HPLC Method for the Determination of Losartan Potassium ... · RP-HPLC Method for the Determination of Losartan Potassium and Ramipril in Combined Dosage Form ... Brenner BM, Cooper

www.ijpsonline.com

Indian Journal of Pharmaceutical Sciences 111January - February 2010

and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

2. Sleight P, Yusuf S, Pogue J. Blood-pressure reduction and cardiovascular risk in the HOPE study. Lancet 2001;358:2130-1.

3. Wright JT Jr, Bakris G, Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. J Am Med Assn 2002;288:2421-31.

4. McCarthy KE, Wang Q, Tsai EW, Gilbert RE, Ip DP, Brooks MA. Determination of losartan and its degradants in COZAAR tablets by reversed-phase high-performance thin-layer chromatography. J Pharm Biomed Anal 1998;17:671-7.

5. Williams RC, Alasandro MS, Fasone VL, Boucher RJ, Edwards JF. Comparison of liquid chromatography, capillary electrophoresis and super-critical fl uid chromatography in the determination of Losartan Potassium drug substance in Cozaar tablets. J Pharm Biomed Anal 1996;14:1539-46.

6. Polinko M, Riffel K, Song H, Lo MW. Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2003;33:73-84.

7. Furtek CI, Lo MW. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Pharm Biomed Anal 1997;15:1021-9.

8. Soldner A, Spahn-Langguth H, Mutschler E. HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material

of humans and rats. J Pharm Biomed Anal 1998;16:863-73.9. Yeung PK, Jamieson A, Smith GJ, Fice D, Pollak PT. Determination

of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection. Int J Pharm 2000;204:17-22.

10. Iwasa T, Takano T, Hara K, Kamei T. Method for the simultaneous determination of losartan and its major metabolite, EXP-3174, in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;734:325-30.

11. Lastra OC, Lemus IG, Sanchez HJ, Perez RF. Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets. J Pharm Biomed Anal 2003;33:175-80.

12. Ansari M, Kazemipour M, Khosravi F, Baradaran M. A comparative study of fi rst-derivative spectrophotometry and high-performance liquid chromatography applied to the determination of losartan potassium in tablets. Chem Pharm Bull 2004;52:1166-70.

13. Prabhakar AH, Giridhar R. A rapid colorimetric method for the determination of Losartan potassium in bulk and in synthetic mixture for solid dosage form. J Pharm Biomed Anal 2002;27:861-6.

14. Gandhimathi M. HPLC determination of losartan pottassium and ramipril in tablets. Indian drugs 2004;41:120-2.

Accepted 4 January 2010Revised 14 September 2009

Received 17 August 2008Indian J. Pharm. Sci., 2010, 72 (1): 108-111

Spectrophotometric Estimation of Olmesartan Medoxomil and Hydrochlorothiazide in TabletA. R. ROTE* AND P. D. BARIDepartment of Pharmaceutical Chemistry, MGV’s Pharmacy College, Panchavati, Mumbai Agra Road, Nashik-422 003, India

Rote and Bari: Spectrophotometric Estimation of Olmesartan and Hydrochlorothiazide

A simultaneous determination of olmesartan medoxomil and hydrochlorothiazide by absorption ratio spectrophotometric method has been developed in combined tablet dosage form. The method is based on measurements of absorbance at isoabsoptive point. The Beer’s law obeys in the range of 10–30 µg/ml for both olmesartan medoxomil and hydrochlorothiazide respectively. The proposed method was validated by performing recovery study and statistically.

Key words: Hydrochlorothiazide, Olmesartan medoxomil, UV spectrophotometry

*Address for correspondenceE-mail: [email protected]

Olmesartan medoxomil (OLM) is a prodrug and is hydrolyzed to the active olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. It is chemically, 2,3-dihydroxy-2-butenyl4-

(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1Htetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate,cyclic-2,3-carbonate. Hydrochlorothiazide (HCT) is one of the oldest and widely used thiazide diuretics. A literature survey revealed that OLM is not yet offi cial in any pharmacopoeia. Several analytical methods have been reported for the determination of olmesartan medoxomil in biological fluids includes LC-MS-MS[1], degradation product HPLC[2], HPTLC[3]. One

Azhar
Rectangle